Past Presentation Materials

Presentation Materials

FY2023

• Second Quarter Financial Results for FY2023 - November 7, 2023
• First Quarter Financial Results for FY2023 - August 2, 2023
• <Presentation Material> CTAD Conference: Late-Breaking Symposium 4 – Lecanemab for early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers, and Novel Subcutaneous Administration - October 24, 2023
• Meeting to Exchange Opinionson Value Creation Report 2023 and ESG - October 17, 2023

FY2022

• Annual Financial Results Presentation for FY2022 - May 15, 2023
• Third Quarter Financial Results for FY2022 - February 6, 2023
• Second Quarter Financial Results for FY2022 - November 7, 2022
• First Quarter Financial Results for FY2022 - August 5, 2022
• Information Meeting (March 10, 2023) - March 10, 2023
• Press Conference - March 9, 2023
• <Presentation Material> Eisai’s Approach to U.S. Pricing for LEQEMBI™ (lecanemab), a Treatment for Early Alzheimer’s Disease (January 7, 2023) - January 7, 2023
• <Presentation Material> Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 - November 21, 2022
• <Eisai Media/Investor Conference> LECANEMAB PHASE 3 STUDY MET PRIMARY ENDPOINT - September 28, 2022
• Meeting of Value Creation Report and ESG - September 21, 2022
• Eisai R&D Basic Meeting - September 13, 2022

FY2021

• Annual Financial Results Presentation for FY2021 - May 13, 2022
• Third Quarter Financial Results for FY2021 - February 3, 2022
• Second Quarter Financial Results for FY2021 - November 1, 2021
• First Quarter Financial Results for FY2021 - August 4, 2021
• Information Meeting (March 16, 2022) - March 16, 2022
• CTAD：Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma Aβ 42/40 Ratio with Changes in Brain Amyloid PET SUVr, and Safety from the Core and OLE of the Phase 2 POC Study, in Subjects with Early AD [Presentation Material] - November 4, 2021

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline
• AAIC：Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study - July 30, 2021

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline

FY2020

• Annual Financial Results Presentation for FY2020 - May 12, 2021
• Third Quarter Financial Results for FY2020 - February 3, 2021
• Second Quarter Financial Results for FY2020 - November 5, 2020
• First Quarter Financial Results for FY2020 - August 3, 2020
• Information Meeting - March 26, 2021
• FY2020 Meeting of Integrated Report and ESG - October 13, 2020

FY2019

• Annual Financial Results Presentation for FY2019 - May 13, 2020
• Third Quarter Financial Results for FY2019 - January 31, 2020
• Second Quarter Financial Results for FY2019 - October 28, 2019
• First Quarter Financial Results for FY2019 - July 31, 2019
• Information Meeting - March 6, 2020
• FY2019 Meeting of Integrated Report and ESG - October 16, 2019
• Eisai Scientific Meeting 2019 Presentation Material - April 23, 2019

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline

FY2018

• Annual Financial Results Presentation for FY2018 - May 13, 2019
• Third Quarter Financial Results Presentation for FY2018 - February 4, 2019
• Second Quarter Financial Results Presentation for FY2018 - November 1, 2018
• 1st Quarter Financial Results - August 1, 2018
• Press Conference - March 9, 2023
• Information Meeting - March 8, 2019
• Press Conference - March 7, 2019
• Presentation Material of Latest Data from Phase II Clinical Study on BAN2401 at 2018 Clinical Trials on Alzheimer's Disease (CTAD) Symposium - October 25, 2018

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline
• FY2018 Meeting of Integrated Report and ESG - October 16, 2018
• <The Media/Investor Conference> Hepatocellular Carcinoma – Latest Trends in Diagnostics and Treatment - September 18, 2018

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline
• The Media/Investor Conference
  Results of Phase II Clinical Study of BAN2401 Presented at the Alzheimer’s Association International Conference (AAIC) 2018 - July 26, 2018

  Cautionary Statement and Acknowledgment

  By proceeding further, you acknowledge and agree that your access to this presentation material, which has been posted in the “Presentations” IR section of the Eisai corporate website, is provided for informational purposes for use by media and investors only and may include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

  In addition, this presentation material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements.

  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency examination periods and obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • The Company cannot guarantee the actual outcomes and results for any forward-looking statements.
  • Furthermore, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  • Accept
  • Decline

FY2017

• Financial Results Presentation - May 15, 2018
• 3rd Quarter Financial Results - February 2, 2018
• Semiannual Financial Results - November 1, 2017
• 1st Quarter Financial Results - August 2, 2017
• Media Conference - March 29, 2018
• Information Meeting 2018 - March 9, 2018
• Press Conference 2018 - March 8, 2018
• The Media/Investor Conference (Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai's In-house Discovered Anticancer Agent LENVIMA) - March 8, 2018
• The Media / Investor Conference (Eisai Expands Existing Collaboration Agreement with Biogen to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab) - October 24, 2017
• Meeting of Integrated Report and ESG - October 3, 2017

FY2016

• Financial Results Presentation - May 10, 2017
• 3rd Quarter Financial Results - February 2, 2017
• Semiannual Financial Results - October 31, 2016
• 1st Quarter Financial Results - August 3, 2016
• Information Meeting 2017 - March 10, 2017
• Press Conference 2017 - March 9, 2017
• Meeting of Integrated Report and ESG - December 26, 2016
• Eisai Scientific Day (New York) - June 29, 2016

FY2015

• Financial Results Presentation - May 13, 2016
• 3rd Quarter Financial Results - February 2, 2016
• Semiannual Financial Results - October 30, 2015
• 1st Quarter Financial Results - July 31, 2015
• Information Meeting 2016 - March 4, 2016
• Press Conference 2016 - March 3, 2016
• Press Conference Concerning the Integration of the Gastrointestinal Disease Business of Eisai Co., Ltd. and AJINOMOTO PHARMACEUTICALS CO., LTD. by Absorption-Type Split - October 15, 2015

FY2014

• Financial Results Presentation - May 14, 2015
• 3rd Quarter Financial Results - January 30, 2015
• Semiannual Financial Results - October 30, 2014
• 1st Quarter Financial Results - August 1, 2014
• Information Meeting 2015 - March 6, 2015
• Press Conference 2015 - March 5, 2015

FY2013

• Financial Results Presentation - May 13, 2013
• 3rd Quarter Financial Results - February 3, 2014
• Semiannual Financial Results - November 1, 2013
• 1st Quarter Financial Results - August 1, 2013
• Information Meeting 2014 - March 7, 2014
• Press Conference 2014 - March 6, 2014

FY2012

• Financial Results Presentation - May 13, 2013
• 3rd Quarter Financial Results - February 1, 2013
• Semiannual Financial Results - November 1, 2012
• 1st Quarter Financial Results - August 1, 2012
• Information Meeting 2013 - March 8, 2013
• Press Conference 2013 - March 7, 2013

FY2011

• Financial Results Presentation - May 15, 2012
• 3rd Quarter Financial Results - February 2, 2012
• Semiannual Financial Results - November 1, 2011
• 1st Quarter Financial Results - August 2, 2011
• Information Meeting 2012 - March 2, 2012
• Press Conference 2012 - March 1, 2012
• Production Creation Meeting (Tokyo) 2011 - June 29, 2011

FY2010

• Financial Results Presentation - May 13, 2011
• 3rd Quarter Financial Results - February 1, 2011
• Semiannual Financial Results - October 28, 2010
• 1st Quarter Financial Results - July 30, 2010
• PRESS CONFERENCE REGARDING APPROVAL OF HALAVEN™ - November 16, 2010
• Information Meeting 2011 - March 4, 2011
• Press Conference 2011 - March 3, 2011
• CONFERENCE REGARDING HIGHER DOSE ARICEPT 23MG TABLETS - July 27, 2010

FY2009

• Financial Results Presentation - May 14, 2010
• 3rd Quarter Financial Results - February 2, 2010
• Semiannual Financial Results - October 30, 2009
• 1st Quarter Financial Results - July 31, 2009
• Information Meeting 2010 - March 5, 2010
• Product Creation Meeting - December 18, 2009

FY2008

• Financial Results Presentation - May 14, 2009
• 3rd Quarter Financial Results - January 30, 2009
• Semiannual Financial Results - October 31, 2008
• 1st Quarter Financial Results - July 31, 2008
• Information Meeting Presentation - February 27, 2009

FY2007

• Financial Results Presentation - May 14, 2008
• Meeting regarding Revised Business Forecast for Fiscal Year Ended March 31, 2008 - April 21, 2008
• 3rd Quarter Financial Results - February 1, 2008
• Semiannual Financial Results - October 30, 2007
• 1st Quarter Financial Results - July 31, 2007
• Information Meeting Presentation - March 4, 2008
• Meeting regarding MGI PHARMA Acquisition - December 10, 2007
• Eisai R&D Meeting - July 17, 2007

FY2006

• Financial Results Presentation - May 15, 2007
• 3rd Quarter Financial Results - February 2, 2007
• Semiannual Financial Results - October 31, 2006
• 1st Quarter Financial Results - July 31, 2006
• Analyst Meeting regarding Morphotek Acquisition - March 22, 2007
• Information Meeting Presentation - March 2, 2007

FY2005

• Financial Results Presentation - May 16, 2006
• 3rd Quarter Financial Results - February 2, 2006
• Semiannual Financial Results - October 31, 2005
• 1st Quarter Financial Results - July 29, 2005
• Information Meeting Presentation - March 3, 2006
• Eisai R&D Meeting - August 30, 2005

FY2004

• Financial Results Presentation - May 16, 2005
• 3rd Quarter Financial Results - February 2, 2005
• Semiannual Financial Results - October 29, 2004
• 1st Quarter Financial Results - July 30, 2004
• Information Meeting Presentation - March 3, 2005
• R&D Information Meeting - September 1, 2004

FY2003

• Financial Results Presentation - May 11, 2004
• 3rd Quarter Financial Results - January 30, 2004
• Semiannual Financial Results - November 5, 2003
• 1st Quarter Financial Results - July 30, 2003
• Information Meeting Presentation - February 27, 2004

FY2002

• Financial Results - May 13, 2003
• Semiannual Financial Results-1 - November 6, 2002
• Semiannual Financial Results-2 - November 6, 2002
• Information Meeting Presentation - February 28, 2003

Other Presentation Materials

• July 20, 2023

  Alzheimer’s Association International Conference (AAIC)　

• January 9, 2019

  37th Annual J.P. Morgan Healthcare Conference

• March 7, 2012

  Presentation Material for Daiwa Investment Conference Tokyo 2012

• March 9, 2011

  Presentation Material for Daiwa Investment Conference Tokyo 2011

• February 9, 2010

  Presentation Material for Citigroup Global Pharmaceutical Seminar 2010

• December 2, 2009

  Presentation Material for Nomura Investment Forum 2009

• September 30, 2009

  Presentation Material for Deutsche Securities Japan Pharmaceutical Conference 2009

• December 2, 2008

  Presentation Material for Nomura Investment Forum 2008

• September 16, 2008

  Presentation Material for 2008 Merrill Lynch Japan Conference “Value to Growth”

• February 6, 2008, audio webcast is available for 13 days

  Presentation Material for Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

• November 29, 2007

  Mizuho Investment Conference 2007

• September 28, 2007

  Presentation Material for Deutsche Securities Japan Pharmaceuticals Conference 2007

• September 13, 2007

  Presentation Material for 2007 Merrill Lynch Japan Conference 2007

• Sep. 2007

  Presentation Material for EU, US Roadshow

• June 12, 2007

  Presentation Material for Goldman Sachs 28th Annual Global Healthcare Conference

• February 7, 2007

  Presentation Material for Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

• December 4, 2006

  Presentation Material for Nomura Investment Forum 2006

• September 14, 2006

  Presentation Material for Deutsche Securities Japan Pharmaceuticals Conference 2006

• September 7, 2006

  Presentation Material for 2006 Merrill Lynch Japan Conference “New Horizons”

• June 13, 2006

  Presentation Material for Goldman Sachs 27th Annual Global Healthcare Conference

• February 7, 2006

  The Presentation Material for Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference*Errors in slide no.19 have been corrected (February 15)

• September 14, 2005

  Presentation Material for Morgan Stanley Japan Equity Conference

• September 7, 2005

  Presentation Material for 2005 Merrill Lynch Japan Conference “A Global Power”

• June 15, 2005

  Presentation Material for Goldman Sachs 26th Annual Global Healthcare Conference

• June 2005

  Presentation Material for US Roadshow

• February 8, 2005

  The Presentation Material for Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

Presentations

The files are in Adobe PDF Format. To view them you will need to download the Adobe Reader.
Adobe Reader, the Acrobat logo are trademarks of Adobe Systems Incorporated.